AmideBio licenses Alzheimer drug

BOULDER — Biotechnology company AmideBio LLC signed an agreement with the University of Colorado for rights to commercialize Alzheimer’s drugs being researched at the Boulder campus.

Terms of the deal between the Boulder-based company and CU were not disclosed. A representative from the CU Technology Transfer Office did not immediately return a call for comment.

Researcher Michael Stowell recently discovered a molecular target in the human body that is degraded by Alzheimer’s, and his team believes that it could create a drug to disrupt that degradation, CU said in a press statement. The team hopes to begin testing a new drug candidate…